CL2015000344A1 - Uso de un hidrolizado de caseina como agente antiherpético y composicion farmaceutica que comprende dicho hidrolizado. - Google Patents

Uso de un hidrolizado de caseina como agente antiherpético y composicion farmaceutica que comprende dicho hidrolizado.

Info

Publication number: CL2015000344A1
Authority: CL; Chile
Prior art keywords: hydrolyzate; pharmaceutical composition; casein; antiherpetic agent; antiherpetic
Prior art date: 2012-08-23

Application number

CL2015000344A

Other languages

English (en)

Inventor

Winkler Pere Adell

Zarco Guillermo Lopez

Original Assignee

Ntd Labs S L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-23

Filing date

2015-02-13

Publication date

2015-06-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49585441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000344(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-02-13 Application filed by Ntd Labs S L filed Critical Ntd Labs S L

2015-06-05 Publication of CL2015000344A1 publication Critical patent/CL2015000344A1/es

Links

230000003602 anti-herpes Effects 0.000 title 1
239000005018 casein Substances 0.000 title 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title 1
235000021240 caseins Nutrition 0.000 title 1
239000003795 chemical substances by application Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CL2015000344A 2012-08-23 2015-02-13 Uso de un hidrolizado de caseina como agente antiherpético y composicion farmaceutica que comprende dicho hidrolizado. CL2015000344A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES201231324A ES2444299B1 (es)	2012-08-23	2012-08-23	Uso de un hidrolizado de caseina como agente antiherpético

Publications (1)

Publication Number	Publication Date
CL2015000344A1 true CL2015000344A1 (es)	2015-06-05

Family

ID=49585441

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2015000344A CL2015000344A1 (es)	2012-08-23	2015-02-13	Uso de un hidrolizado de caseina como agente antiherpético y composicion farmaceutica que comprende dicho hidrolizado.

Country Status (13)

Country	Link
US (1)	US9662369B2 (es)
EP (1)	EP2887951B1 (es)
AU (1)	AU2013307236B2 (es)
BR (1)	BR112015003828A2 (es)
CA (1)	CA2882790C (es)
CL (1)	CL2015000344A1 (es)
CR (1)	CR20150130A (es)
ES (2)	ES2444299B1 (es)
MX (1)	MX357829B (es)
PE (1)	PE20150558A1 (es)
SG (1)	SG11201501223QA (es)
WO (1)	WO2014030125A2 (es)
ZA (1)	ZA201501071B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2544153B1 (es)	2014-02-24	2016-06-06	Ntd Labs, S.L.	Uso de un hidrolizado de caseína como agente antiviral

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8529880D0 (en)	1985-12-04	1986-01-15	Medical Res Council	Polypeptide & pharmaceutical composition
US4795740A (en)	1986-05-20	1989-01-03	Cohen Eric A	Antiviral peptides and means for treating herpes infections
EP0292255A3 (en)	1987-05-22	1990-08-22	Merck & Co. Inc.	Inhibitor of ribonucleotide reductase
US5120639A (en)	1989-04-03	1992-06-09	E. R. Squibb & Sons, Inc.	Selective inhibition of dna polymerase
DE3922453A1 (de)	1989-07-07	1991-01-17	Gauri Kailash Kumar	Pharmakologisch wirksame produkte aus molkeproteinhydrolysaten und verfahren zu deren gewinnung
DK31991D0 (da)	1991-02-25	1991-02-25	Carlbiotech Ltd As	Peptid og farmaceutisk praeparat indeholdende et saadant peptid
WO1992017191A1 (en)	1991-04-01	1992-10-15	Cytoven	Pharmaceutical dipeptide compositions and methods of use thereof
CA2134119A1 (en)	1992-04-23	1993-11-11	Michael Twist	Treatment of herpesvirus infection
US5441936A (en)	1993-12-07	1995-08-15	Houghten Pharmaceuticals, Inc.	Antiviral peptides
GB9615730D0 (en)	1996-07-26	1996-09-04	Medical Res Council	Anti-viral agent 1
WO2001057072A2 (en)	2000-02-07	2001-08-09	Wisconsin Alumni Research Foundation	Pharmacologically active antiviral peptides and methods of their use
CN100506981C (zh) *	2000-12-07	2009-07-01	Dsmip资产有限公司	富含具有羧基末端脯氨酸残基的肽的蛋白质水解产物
AU2003277644A1 (en) *	2002-11-29	2004-06-23	Morinaga Milk Industry Co., Ltd.	Cysteine protease inhibitor
EP1922054B1 (en) *	2004-06-28	2012-03-28	DSM IP Assets B.V.	Cosmetic compositions containing protein hydrolysates
DK1778271T3 (da)	2004-08-18	2009-02-16	Ipf Pharmaceuticals Gmbh	Peptid til behandling af herpesvirusinfektioner
US20090176743A1 (en)	2005-07-29	2009-07-09	Priscilla Schaffer	Methods for treating or preventing reactivation of a latent herpesvirus infection
TW201000634A (en) *	2008-05-30	2010-01-01	Dsm Ip Assets Bv	Proline-specific protease
US20090311236A1 (en) *	2008-06-11	2009-12-17	Immune @Work, Inc.	Therapeutic Peptide Compositions And Methods Of Making And Using Same
WO2011138489A1 (es) *	2010-05-06	2011-11-10	Consejo Superior De Investigaciones Científicas (Csic)	Uso de hidrolizados de caseínas como antivirales

2012
- 2012-08-23 ES ES201231324A patent/ES2444299B1/es not_active Expired - Fee Related
2013
- 2013-08-21 MX MX2015002182A patent/MX357829B/es active IP Right Grant
- 2013-08-21 ES ES13792072.4T patent/ES2631927T3/es active Active
- 2013-08-21 US US14/422,951 patent/US9662369B2/en active Active
- 2013-08-21 SG SG11201501223QA patent/SG11201501223QA/en unknown
- 2013-08-21 WO PCT/IB2013/056775 patent/WO2014030125A2/en not_active Ceased
- 2013-08-21 EP EP13792072.4A patent/EP2887951B1/en active Active
- 2013-08-21 CA CA2882790A patent/CA2882790C/en active Active
- 2013-08-21 AU AU2013307236A patent/AU2013307236B2/en active Active
- 2013-08-21 BR BR112015003828A patent/BR112015003828A2/pt not_active IP Right Cessation
- 2013-08-21 PE PE2015000224A patent/PE20150558A1/es not_active Application Discontinuation
2015
- 2015-02-13 CL CL2015000344A patent/CL2015000344A1/es unknown
- 2015-02-16 ZA ZA2015/01071A patent/ZA201501071B/en unknown
- 2015-03-12 CR CR20150130A patent/CR20150130A/es unknown

Also Published As

Publication number	Publication date
MX2015002182A (es)	2015-07-06
CA2882790A1 (en)	2014-02-27
AU2013307236B2 (en)	2016-11-17
WO2014030125A3 (en)	2014-04-10
EP2887951B1 (en)	2017-04-05
ZA201501071B (en)	2016-01-27
US9662369B2 (en)	2017-05-30
CR20150130A (es)	2015-05-13
MX357829B (es)	2018-07-25
ES2444299A1 (es)	2014-02-24
ES2444299B1 (es)	2014-12-12
BR112015003828A2 (pt)	2017-07-04
CA2882790C (en)	2017-07-04
WO2014030125A2 (en)	2014-02-27
US20150343010A1 (en)	2015-12-03
ES2631927T3 (es)	2017-09-06
AU2013307236A1 (en)	2015-03-05
SG11201501223QA (en)	2015-03-30
PE20150558A1 (es)	2015-05-14
EP2887951A2 (en)	2015-07-01

Similar Documents

Publication	Publication Date	Title
CL2014001930A1 (es)	2014-10-03	Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
BR112015030525A2 (pt)	2017-07-25	nanopartícula, kit, método de preparação de uma nanopartícula, e uso da nanopartícula
BR112016003229A2 (pt)	2017-08-01	Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
CL2014003370A1 (es)	2015-02-06	Composición acuosa estable de anticuerpos anti-baffr; y dispositivo de suministro de la composición.
CL2015001486A1 (es)	2015-10-16	Composición que comprende agentes de control biológico.
CR20150380A (es)	2015-08-21	Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
BR112014029906A2 (pt)	2018-04-17	composições compreendendo um agente de controle biológico e um inseticida.
BR112014029122A2 (pt)	2017-06-27	composições que compreendem um agente de controle biológico e um inseticida
BR112014029222A2 (pt)	2017-06-27	composições que compreendem um agente de controle biológico e um inseticida
BR112014029118A2 (pt)	2017-06-27	composições que compreendem um agente de controle biológico e um inseticida
FR3003568B1 (fr)	2018-06-29	Composition comprenant hf et 3,3,3-trifluoro-2-chloropropene
CL2015001116A1 (es)	2015-09-25	Composición y uso de dimeros de alquil cetena hidrogenados.
CL2014003148A1 (es)	2015-02-27	Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
CL2014003135A1 (es)	2015-01-09	Formulacion que comprende un quelato de oligonucleotidos; y sus usos.
BR112015014885A2 (pt)	2017-07-11	combinação de agentes ativos, composição cosmética e/ou dermatológica e processo para a preparação de uma composição de agentes ativos.
BR112014026873A2 (pt)	2017-06-27	método cosmético, composição cosmética e uso.
BR112015012443A2 (pt)	2017-07-11	composição de limpeza, método de limpeza do corpo humano, uso da composição e método para prover limpeza
PL3064491T3 (pl)	2020-04-30	Pochodna sulfonamidowa i jej zastosowanie medyczne
CL2014003525A1 (es)	2015-04-10	Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CL2015001458A1 (es)	2015-09-21	Composición simbiotica y el uso de la misma.
BR112014017445A2 (pt)	2017-12-19	composição, uso de uma composição, corpo lignocelulósico, e, método para preparar uma composição
PT2408913T (pt)	2017-03-07	Péptidos neil3 e vacinas que incluem os mesmos
BR112014025416A2 (pt)	2013-10-17	AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
BR112017007753A2 (pt)	2018-06-19	uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
CL2015002110A1 (es)	2016-06-17	Parvovirus porcino 5b, métodos de uso y vacuna